Inhibition of VEGFR3 preferentially affects CD133+ OCSCs, leading to the downregulation of BRCA1 and BRCA2, and thereby restoring chemosensitivity in previously resistant ovarian cancer cell lines [236]. This evidence concerns the gene BRCA1 and ovarian carcinoma.